Journal
BRITISH JOURNAL OF CANCER
Volume 113, Issue 9, Pages 1282-1288Publisher
SPRINGERNATURE
DOI: 10.1038/bjc.2015.351
Keywords
osteosarcoma; DCE-MRI; 18F-FDG PET; prognostic factors; antiangiogenic therapy; drug exposure
Categories
Funding
- Cancer Center Support Grant [P30 CA-21765]
- National Cancer Institute at the National Institutes of Health (Bethesda, MD, USA) [CA-23099]
- American Lebanese Syrian Associated Charities (ALSAC
- Memphis, TN, USA)
Ask authors/readers for more resources
Background: The purpose of this study was to assess the impact of bevacizumab alone and in combination with cytotoxic therapy on tumour vasculature in osteosarcoma (OS) using DCE-MRI. Methods: Six DCE-MRI and three 18F-FDG PET examinations were scheduled in 42 subjects with newly diagnosed OS to monitor the response to antiangiogenic therapy alone and in combination with cytotoxic therapy before definitive surgery (week 10). Serial DCE-MRI parameters (K-trans, v(p), and v(e)) were examined for correlation with FDG-PET (SUVmax) and association with drug exposure, and evaluated with clinical outcome. Results: Ktrans (P = 0.041) and vp (P = 0.001) significantly dropped from baseline at 24 h after the first dose of bevacizumab alone, but returned to baseline by 72 h. Greater exposure to bevacizumab was correlated with larger decreases in vp at day 5 (P = 0.04) and week 10 (P = 0.02). A lower Ktrans at week 10 was associated with greater percent necrosis (P = 0.024) and longer event-free survival (P = 0.034). Conclusions: This is the first study to demonstrate significant changes of the plasma volume fraction and vascular leakage in OS with bevacizumab alone. The combination of demonstrated associations between drug exposure and imaging metrics, and imaging metrics and patient survival during neoadjuvant therapy, provides a compelling rationale for larger studies using DCE-MRI to assess vascular effects of therapy in OS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available